Published on . Prices and market conditions may have changed since then.
Sun Pharmaceutical Industries (NSE: SUNPHARMA) gained 2.03% on Wednesday, pushing the stock back toward ₹1,700 and reviving bullish interest after weeks of range-bound movement. The bounce comes just in time, with broader markets steadying and traders rotating back into defensive names.
The rally follows a relatively quiet stretch for Sun Pharma, where the stock drifted lower from its April highs above ₹1,850. But today’s push signals that buyers are re-entering near the lower end of the short-term channel, with ₹1,680–₹1,700 now shaping up as a key battleground.
Sun Pharma Technical Outlook: Bouncing From Support
The chart shows a solid recovery off the ₹1,650 zone, which acted as support in early May. While the larger trend remains bullish, recent price action has been consolidative, not corrective.
- RSI is at 45.69, pointing to a recovery from oversold territory
- MACD remains below zero, but the gap is narrowing – an early sign of momentum shift
- Immediate resistance now stands at ₹1,740, followed by a bigger test at ₹1,800
- Support rests at ₹1,660, with deeper demand near ₹1,620 if weakness returns
The daily structure is beginning to tilt upward again, but bulls still need a decisive break above ₹1,740 to call this more than a relief rally.
Sun Pharma Share Price Forecast: Room to Reclaim ₹1,800?
Momentum looks better than it did a week ago. If Sun Pharma can close above ₹1,740 this week, the path toward ₹1,800 opens up quickly. Beyond that, a retest of the April high near ₹1,850 isn’t off the table, but it depends on broader sector participation and fresh institutional buying.
For now, this bounce looks like the start of a recovery, not a breakout. But in a market rotating into pharma, Sun is starting to feel relevant again.